-
Je něco špatně v tomto záznamu ?
Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum
V. Rechl, A. Ranft, V. Bhadri, B. Brichard, S. Collaud, S. Cyprova, H. Eich, T. Ek, H. Gelderblom, J. Hardes, LM. Haveman, W. Hartmann, P. Hauser, P. Heesen, H. Jürgens, J. Kanerva, T. Kühne, A. Raciborska, J. Rascon, A. Streitbürger, Y....
Status neindexováno Jazyk angličtina Země Egypt
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1997
PubMed Central
od 1997
Europe PubMed Central
od 1997
ProQuest Central
od 2014-01-01 do 2024-01-31
Open Access Digital Library
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Open Access Digital Library
od 1997-01-01
CINAHL Plus with Full Text (EBSCOhost)
od 1997-03-01
Nursing & Allied Health Database (ProQuest)
od 2014-01-01 do 2024-01-31
Wiley-Blackwell Open Access Titles
od 1997
ROAD: Directory of Open Access Scholarly Resources
od 1997
PubMed
38524902
DOI
10.1155/2024/4751914
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Ewing sarcoma (EwS) is a rare and highly malignant bone tumor primarily affecting children, adolescents, and young adults. The pelvis, trunk, and lower extremities are the most common sites, while EwS of the sacrum as a primary site is very rare, and only few studies focusing on this location are published. Due to the anatomical condition, local treatment is challenging in sacral malignancies. We analyzed factors that might influence the outcome of patients suffering from sacral EwS. METHODS: We retrospectively analyzed data of the GPOH EURO-E.W.I.N.G 99 trial and the EWING 2008 trial, with a cohort of 124 patients with localized or metastatic sacral EwS. The study endpoints were overall survival (OS) and event-free survival (EFS). OS and EFS were calculated using the Kaplan-Meier method, and univariate comparisons were estimated using the log-rank test. Hazard ratios (HRs) with respective 95% confidence intervals (CIs) were estimated in a multivariable Cox regression model. RESULTS: The presence of metastases (3y-EFS: 0.33 vs. 0.68; P < 0.001; HR = 3.4, 95% CI 1.7 to 6.6; 3y-OS: 0.48 vs. 0.85; P < 0.001; HR = 4.23, 95% CI 1.8 to 9.7), large tumor volume (≥200 ml) (3y-EFS: 0.36 vs. 0.69; P=0.02; HR = 2.1, 95% CI 1.1 to 4.0; 3y-OS: 0.42 vs. 0.73; P=0.04; HR = 2.1, 95% CI 1.03 to 4.5), and age ≥18 years (3y-EFS: 0.41 vs. 0.60; P=0.02; HR = 2.6, 95% CI 1.3 to 5.2; 3y-OS: 0.294 vs. 0.59; P=0.01; HR = 2.92, 95% CI 1.29 to 6.6) were revealed as adverse prognostic factors. CONCLUSION: Young age seems to positively influence patients` survival, especially in patients with primary metastatic disease. In this context, our results support other studies, stating that older age has a negative impact on survival. Tumor volume, metastases, and the type of local therapy modality have an impact on the outcome of sacral EwS. Level of evidence: Level 2. This trial is registered with NCT00020566 and NCT00987636.
Charles University Motol Child Ren's Hospital Prague Czech Republic
Childhood Cancer Center Queen Silvia Children's Hospital Gothenburg Sweden
Chris O'Brien Lifehouse Camperdown Australia
Clinic of Tumororthopedics University Hospital Essen West German Cancer Centre Essen Germany
Clinics of Children's Diseases Faculty of Medicine Vilnius University Vilnius Lithuania
Department of Oncology Hematology University Children's Hospital Basel Basel Switzerland
Faculty of Medicine and Health University of Sydney Camperdown Australia
German Cancer Consortium Partnersite Essen Germany
Leiden University Medical Center Department of Medical Oncology Leiden NL USA
Patient Representative St Josef's Hospital Bochum University Hospital Bochum Germany
Princess Máxima Center for Pediatric Oncology Department of Solid Tumors Utrecht Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005573
- 003
- CZ-PrNML
- 005
- 20240412131000.0
- 007
- ta
- 008
- 240405e20240316ua f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2024/4751914 $2 doi
- 035 __
- $a (PubMed)38524902
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ua
- 100 1_
- $a Rechl, Victor $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $1 https://orcid.org/0009000728017495
- 245 10
- $a Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum / $c V. Rechl, A. Ranft, V. Bhadri, B. Brichard, S. Collaud, S. Cyprova, H. Eich, T. Ek, H. Gelderblom, J. Hardes, LM. Haveman, W. Hartmann, P. Hauser, P. Heesen, H. Jürgens, J. Kanerva, T. Kühne, A. Raciborska, J. Rascon, A. Streitbürger, Y. Uhlenbruch, B. Timmermann, J. Kersting, MT. Pham, U. Dirksen
- 520 9_
- $a BACKGROUND: Ewing sarcoma (EwS) is a rare and highly malignant bone tumor primarily affecting children, adolescents, and young adults. The pelvis, trunk, and lower extremities are the most common sites, while EwS of the sacrum as a primary site is very rare, and only few studies focusing on this location are published. Due to the anatomical condition, local treatment is challenging in sacral malignancies. We analyzed factors that might influence the outcome of patients suffering from sacral EwS. METHODS: We retrospectively analyzed data of the GPOH EURO-E.W.I.N.G 99 trial and the EWING 2008 trial, with a cohort of 124 patients with localized or metastatic sacral EwS. The study endpoints were overall survival (OS) and event-free survival (EFS). OS and EFS were calculated using the Kaplan-Meier method, and univariate comparisons were estimated using the log-rank test. Hazard ratios (HRs) with respective 95% confidence intervals (CIs) were estimated in a multivariable Cox regression model. RESULTS: The presence of metastases (3y-EFS: 0.33 vs. 0.68; P < 0.001; HR = 3.4, 95% CI 1.7 to 6.6; 3y-OS: 0.48 vs. 0.85; P < 0.001; HR = 4.23, 95% CI 1.8 to 9.7), large tumor volume (≥200 ml) (3y-EFS: 0.36 vs. 0.69; P=0.02; HR = 2.1, 95% CI 1.1 to 4.0; 3y-OS: 0.42 vs. 0.73; P=0.04; HR = 2.1, 95% CI 1.03 to 4.5), and age ≥18 years (3y-EFS: 0.41 vs. 0.60; P=0.02; HR = 2.6, 95% CI 1.3 to 5.2; 3y-OS: 0.294 vs. 0.59; P=0.01; HR = 2.92, 95% CI 1.29 to 6.6) were revealed as adverse prognostic factors. CONCLUSION: Young age seems to positively influence patients` survival, especially in patients with primary metastatic disease. In this context, our results support other studies, stating that older age has a negative impact on survival. Tumor volume, metastases, and the type of local therapy modality have an impact on the outcome of sacral EwS. Level of evidence: Level 2. This trial is registered with NCT00020566 and NCT00987636.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ranft, Andreas $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $u German Cancer Consortium, Partnersite, Essen, Germany $1 https://orcid.org/0000000344247569
- 700 1_
- $a Bhadri, Vivek $u Chris O'Brien Lifehouse, Camperdown, Australia $u Faculty of Medicine and Health, University of Sydney, Camperdown, Australia $1 https://orcid.org/0000000298142060
- 700 1_
- $a Brichard, Benedicte $u Cliniques Universitaires Saint Luc, Department of Pediatric Hematology and Oncology, Université Catholique de Louvain, Brussels, Belgium $1 https://orcid.org/0000000327651711
- 700 1_
- $a Collaud, Stephane $u Lung Clinic, Department of Thoracic Surgery, Cologne Merheim Hospital, University of Witten/Herdecke, Witten, Germany $1 https://orcid.org/0000000247491017
- 700 1_
- $a Cyprova, Sona $u Charles University, Motol Child Ren's Hospital, Prague, Czech Republic $1 https://orcid.org/0009000279018432
- 700 1_
- $a Eich, Hans $u Radiotherapy and Radiooncology, University Hospital Muenster, West German Cancer Center Network, Muenster, Germany
- 700 1_
- $a Ek, Torben $u Childhood Cancer Center Queen Silvia Children's Hospital, Gothenburg, Sweden $1 https://orcid.org/000000020518983X
- 700 1_
- $a Gelderblom, Hans $u Leiden University Medical Center, Department of Medical Oncology, Leiden, NL, USA $1 https://orcid.org/0000000192708636
- 700 1_
- $a Hardes, Jendrik $u German Cancer Consortium, Partnersite, Essen, Germany $u Clinic of Tumororthopedics, University Hospital Essen, West German Cancer Centre, Essen, Germany $1 https://orcid.org/0000000284082255
- 700 1_
- $a Haveman, Lianne M $u Princess Máxima Center for Pediatric Oncology, Department of Solid Tumors, Utrecht, Netherlands $1 https://orcid.org/0000000185198906
- 700 1_
- $a Hartmann, Wolfgang $u Gerhard Domagk Institute for Pathology, University Hospital Muenster, West German Cancer Center Network, Muenster, Germany $1 https://orcid.org/0000000276095021
- 700 1_
- $a Hauser, Peter $u Velkey László Child's, Health Center, Borsod-Abaúj-Zemplén County University Teaching Hospital, Miskolc, Hungary $1 https://orcid.org/0000000283078975
- 700 1_
- $a Heesen, Philip $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $1 https://orcid.org/0000000250904935
- 700 1_
- $a Jürgens, Heribert $u Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, West German Cancer Center Network, Münster, Germany
- 700 1_
- $a Kanerva, Jukka $u HUS Helsinki University Hospital, New Children's Hospital, Div. Hematology and Stem Cell Transplantation, Helsinki, Finland $1 https://orcid.org/0000000258396058
- 700 1_
- $a Kühne, Thomas $u Department of Oncology/Hematology, University Children's Hospital Basel, Basel, Switzerland $1 https://orcid.org/0000000273877028
- 700 1_
- $a Raciborska, Anna $u Mother and Child Institute, Department of Oncology and Surgical Oncology for Children and Youth, Warsaw, Poland $1 https://orcid.org/0000000326127934
- 700 1_
- $a Rascon, Jelena $u Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania $u Clinics of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000344206943
- 700 1_
- $a Streitbürger, Arne $u German Cancer Consortium, Partnersite, Essen, Germany $u Clinic of Tumororthopedics, University Hospital Essen, West German Cancer Centre, Essen, Germany $1 https://orcid.org/0009000679432579
- 700 1_
- $a Uhlenbruch, Yasmin $u Patient Representative, St. Josef's Hospital Bochum, University Hospital, Bochum, Germany
- 700 1_
- $a Timmermann, Beate $u German Cancer Consortium, Partnersite, Essen, Germany $u Clinic for Particle Therapy, West German Proton Beam Centre, University Hospital Essen, West German Cancer Centre, German Cancer Research Centre (DKTK), Essen, Germany $1 https://orcid.org/0000000322742008
- 700 1_
- $a Kersting, Josephine $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $u German Cancer Consortium, Partnersite, Essen, Germany $1 https://orcid.org/0009000830959956
- 700 1_
- $a Pham, Minh Thanh $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- 700 1_
- $a Dirksen, Uta $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $u German Cancer Consortium, Partnersite, Essen, Germany $1 https://orcid.org/0000000254357860
- 773 0_
- $w MED00006234 $t Sarcoma $x 1357-714X $g Roč. 2024 (20240316), s. 4751914
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38524902 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130953 $b ABA008
- 999 __
- $a ok $b bmc $g 2075956 $s 1215335
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 2024 $c - $d 4751914 $e 20240316 $i 1357-714X $m Sarcoma $n Sarcoma $x MED00006234
- LZP __
- $a Pubmed-20240405
